Renin Angiotensin Converting Enzyme 2 and COVID‑19: Prevention and Treatment

Marzieh Kafami, Mehdi Nematbakhsh

Abstract


Dear Editor, The 2019 novel corona virus (SARS‑CoV‑2) has already taken on pandemic proportions, having infected more than seven million people in 213 countries. The increased prevalence of the disease as well as involvement of the angiotensin‑converting enzyme 2 (ACE2) have suggested to consider its role in corona virus infection diseases‑2019 (COVID‑19).

Keywords


COVID‑19; COVID‑19; Renin Angiotensin;

Full Text:

PDF

References


Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic

characterisation and epidemiology of 2019 novel coronavirus:

Implications for virus origins and receptor binding. Lancet

;395:565‑74.

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA,

Stahl M, et al. Inhibition of SARS‑CoV‑2 infections in

engineered human tissues using clinical‑grade soluble human

ACE2. Cell 2020;181:905‑13.e7.

McLachlan CS. The angiotensin‑converting enzyme 2 (ACE2)

receptor in the prevention and treatment of COVID‑19 are

distinctly different paradigms. Clin Hypertens 2020;26:14.

Rodríguez‑Puertas R. ACE2 activators for the treatment of

COVID 19 patients. J Med Virol 2020;92:1701‑2.

Prata LO, Rodrigues CR, Martins JM, Vasconcelos PC,

Oliveira FM, Ferreira AJ, et al. Original Research: ACE2

activator associated with physical exercise potentiates the

reduction of pulmonary fibrosis. Exp Biol Med (Maywood)

;242:8‑21.




ijpm_12_448